TFF Pharmaceuticals, Inc. Stock

Stocks

0K30

US87241J2033

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN 18:13:34 31/10/2024 +04 5-day change 1st Jan Change
2.180 EUR +21.79% Intraday chart for TFF Pharmaceuticals, Inc. -.--% -

Valuation: TFF Pharmaceuticals, Inc.

Market Cap 10.52M 9.24M 8.59M 7.88M 14.81M 1.01B 15.04M 102M 39.86M 498M 39.49M 38.64M 1.72B P/E 2022 *
-
P/E 2023 -0.61x
Enterprise Value 5.16M 4.53M 4.21M 3.86M 7.26M 497M 7.37M 50.01M 19.54M 244M 19.36M 18.94M 844M EV / Sales 2022 *
-
EV / Sales 2023 15,920,656x
Free-Float
97.4%
Yield 2022 *
-
Yield 2023 -
3 years 1.42
Extreme 1.42
8
5 years 1.42
Extreme 1.42
8
10 years 1.42
Extreme 1.42
8
Manager TitleAgeSince
Chief Executive Officer 64 14/11/2024
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 64 14/11/2024
Date Insider Type Main position Quantity % Market Cap.
03/07/24 Free

Director

6,330 0.2043%
03/07/24 Free

Director

3,166 0.1022%
03/07/24 Free

Director

3,166 0.1022%
Change 5-day change 1-year change 3-year change Capi.($)
+21.79%-.--%-.--% - 11.02M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.95%+0.75%+403.94%+623.07% 40.13B
-11.75%+4.81%+10.31%+67.50% 36.33B
+5.33%+1.36%+4.10%-8.37% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+7.24%-2.62% - - 16.66B
+2.31%+12.83%+33.14%+145.69% 16.91B
+0.42%-4.46%+4.80%+8.67% 13.05B
+5.45%-1.79%-14.38%-31.19% 13.05B
Average +2.54%+1.50%+49.15%+106.64% 24.38B
Weighted average by Cap. +0.52%+0.77%+75.31%+135.86%

Financials

2022 2023
Net sales 0.5 0.44 0.4 0.37 0.7 47.75 0.71 4.81 1.88 23.47 1.86 1.82 81.16 0.73 0.64 0.6 0.55 1.03 70.67 1.05 7.12 2.78 34.75 2.75 2.7 120.13
Net income -31.77M -27.9M -25.95M -23.81M -44.74M -3.06B -45.43M -308M -120M -1.5B -119M -117M -5.2B -21.24M -18.66M -17.35M -15.92M -29.92M -2.05B -30.38M -206M -80.5M -1.01B -79.75M -78.03M -3.48B
Net Debt -16.42M -14.42M -13.41M -12.31M -23.13M -1.58B -23.48M -159M -62.23M -777M -61.65M -60.32M -2.69B -5.36M -4.71M -4.38M -4.02M -7.55M -516M -7.67M -52.02M -20.32M -254M -20.13M -19.7M -878M
Logo TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Employees
19

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 0K30 Stock